High Dose Cyclophosphamide: Stem Cell Mobilizing Capacity in 21 Patients
Authors:
- Ignazio MajolinoIMIgnazio Majolino
- Rosanna ScimèRSRosanna Scimè
- Stefania VastaSVStefania Vasta
- Serena GentileSGSerena Gentile
- Grace LibertiGLGrace Liberti
- Alessandra SantoroASAlessandra Santoro
- Maria PampinellaMPMaria Pampinella
- Francesco CaroniaFCFrancesco Caronia
- 1 January 1994
- journal article
- clinical trial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 14 (1-2) , 71-77
Abstract
In the present study we assess the antitumor effect and circulating stem cells (CSC) mobilizing capacity of high-dose cyclophosphamide (5 to 7 gr/m2, HDCY). This treatment was given to 21 patients with various hematologic malignancies (8 NHL, 5 MM, 4 HD, 3 CML) excluding 1 with neuroblastoma. All were eligible for later autologous blood stem cell transplantation (ABSCT). To reduce the hematologic toxicity of HDCY, GM CSF was simultaneously administered in 5 patients. HDCY produced a response (as defined by a >50% reduction of previous tumor mass) in 3 out of 12 HD/NHL and 1 out of 3 MM. Patients with CML were not considered to be evaluable for tumor response. Cell collection yields after HDCY varied widely with a range of 1.5 to 169.9 × 104/Kg (median 13.1) CFU-GM and 1.7 to 18.4 × 108/Kg (median 5.8) MNC collected per patient. Hematologic recovery was rapid and sustained with a median of 16 (12-18) days to PMN > 0.5 × 109/L and 14 (11-18) days to Plt > 100.0 × 109/L. Granulocyte recovery was significantly faster after GM-CSF (13 vs 16 days to PMN > 0.5, p = 0.0008). Non hematologic toxicity consisted mainly of nausea and vomiting, but fatal complications occurred in 2 patients, from pulmonary infection in one and from tumor-lysis syndrome in the other. HDCY represents a useful means of increasing collection of CSC, but toxicity is not irrelevant. Whether a similar anti-tumor effect and mobilizing capacity would be offered by single lower intermediate doses of the drug is still to be ascertained.Keywords
This publication has 17 references indexed in Scilit:
- Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cellsBritish Journal of Cancer, 1992
- Conventional intensive therapy can lead to overshoot of PH-negative blood cells in chronic myeloid leukemiaStem Cells, 1992
- Autolo ous blood stem cell transplantation in malignant lymphomas: An itavian cooperative studyStem Cells, 1992
- Selective expression of CD45 isoforms on functional subpopulations of CD34+ hemopoietic cells from human bone marrow.Journal of Experimental Medicine, 1990
- Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1990
- High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignanciesCancer, 1989
- Autologous Bone Marrow TransplantationAnnals of Internal Medicine, 1989
- GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MANThe Lancet, 1988
- Dose: A critical factor in cancer chemotherapyThe American Journal of Medicine, 1980
- Cells Capable of Colony Formation in the Peripheral Blood of ManScience, 1971